Compare BNGO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | LEXX |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 22.7M |
| IPO Year | 2018 | N/A |
| Metric | BNGO | LEXX |
|---|---|---|
| Price | $1.73 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $6.33 | $4.00 |
| AVG Volume (30 Days) | ★ 303.0K | 151.0K |
| Earning Date | 11-13-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,720,000.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | $24.54 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $1.45 | $0.77 |
| 52 Week High | $22.80 | $2.85 |
| Indicator | BNGO | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 55.92 |
| Support Level | $1.59 | $1.00 |
| Resistance Level | $1.88 | $1.15 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 65.12 | 64.00 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.